The complexities of female aging: Four women protagonists in Penelope Lively's novels.

J Aging Stud

Department of English and Linguistics, Universitat de Lleida, Catalunya, Spain. Electronic address:

Published: January 2016

Penelope Lively is a well-known contemporary British author who has published a good number of novels and short stories since she started her literary career in her late thirties. In her novels, Lively looks at the lives of contemporary characters moulded by specific historical as well as cultural circumstances. Four of her novels, published from 1987 to 2004, present middle-aged and older women as their main protagonists. Through the voices and thoughts of these female characters, the reader is presented with a multiplicity of realities in which women find themselves after their mid-fifties within a contemporary context. Being a woman and entering into old age is a double-sided jeopardy which has increasingly been present in contemporary fiction. Scholars such as Simone de Beauvoir (1949) and Susan Sontag (1972) were among the first to point out a "double standard of aging" when they assured that women were punished when showing external signs of aging much sooner than men. In Lively's four novels, the aging protagonists present their own stories and, through them, as well as through the voices of those around them, the reader is invited to go beyond the aging appearance of the female protagonists while challenging the limiting conceptions attached to the old body and, by extension, to the social and cultural overtones associated with old age.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaging.2015.12.007DOI Listing

Publication Analysis

Top Keywords

lively's novels
8
novels
5
complexities female
4
aging
4
female aging
4
women
4
aging women
4
protagonists
4
women protagonists
4
protagonists penelope
4

Similar Publications

Purpose: Mutations in the ATM gene are common in multiple cancers, but clinical studies of therapies targeting ATM-aberrant cancers have yielded mixed results. Refinement of ATM loss of function (LOF) as a predictive biomarker of response is urgently needed.

Experimental Design: We present the first disclosure and preclinical development of a novel, selective ATR inhibitor, ART0380, and test its antitumor activity in multiple preclinical cancer models.

View Article and Find Full Text PDF

The urokinase-type plasminogen activator receptor (uPAR) is an essential regulator for cell signaling in tumor cell proliferation, adhesion, and metastasis. The ubiquitous nature of uPAR in many aggressive cancer types makes uPAR an attractive target for immunotherapy. Here, we present a rapid and successful workflow for developing cross-reactive anti-uPAR recombinant antibodies (rAbs) using high-throughput optofluidic screening of single B-cells from human uPAR-immunized mice.

View Article and Find Full Text PDF

MicroRNAs in Synovial Pathology Associated With Osteoarthritis.

Front Med (Lausanne)

August 2020

Arthritis Program, Krembil Research Institute, University Health Network, Toronto, ON, Canada.

Osteoarthritis (OA) is the most common type of arthritis, a disease that affects the entire joint. The relative involvement of each tissue, and their interactions, add to the complexity of OA, hampering our understanding of the underlying molecular mechanisms, and the generation of a disease modifying therapy. The synovium is essential in maintaining joint homeostasis, and pathologies associated with the synovium contribute to joint destruction, pain and stiffness in OA.

View Article and Find Full Text PDF

Sequencing identifies a distinct signature of circulating microRNAs in early radiographic knee osteoarthritis.

Osteoarthritis Cartilage

November 2020

Arthritis Program, Krembil Research Institute, University Health Network, Toronto, ON, Canada; Department of Surgery, Faculty of Medicine, University of Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. Electronic address:

Objective: MicroRNAs act locally and systemically to impact osteoarthritis (OA) pathophysiology, but comprehensive profiling of the circulating miRNome in early vs late stages of OA has yet to be conducted. Sequencing has emerged as the preferred method for microRNA profiling since it offers high sensitivity and specificity. Our objective was to sequence the miRNome in plasma from 91 patients with early [Kellgren-Lawrence (KL) grade 0 or 1 (n = 41)] or late [KL grade 3 or 4 (n = 50)] symptomatic radiographic knee OA to identify unique microRNA signatures in each disease state.

View Article and Find Full Text PDF

Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes.

ACS Med Chem Lett

August 2013

Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.

GPR142 is a G protein-coupled receptor that is predominantly expressed in pancreatic β-cells. GPR142 agonists stimulate insulin secretion in the presence of high glucose concentration, so that they could be novel insulin secretagogues with reduced or no risk of hypoglycemia. We report here the optimization of HTS hit compound 1 toward a proof of concept compound 33, which showed potent glucose lowering effects during an oral glucose tolerance test in mice and monkeys.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!